IFF
19.11.2020 22:17:08 CET | Business Wire | Press release
Regulatory News:
International Flavors and Fragrances (“IFF”) (NYSE: IFF) (Euronext Paris: IFF) (TASE: IFF) announced today that following a comprehensive review of the trading volume, costs and administrative requirements related to its listing on Euronext Paris, it has decided to request the voluntary delisting of its shares (the “IFF Shares”) (ISIN US4595061015) from Euronext Paris. The Board of Euronext has approved this request.
Following the delisting from Euronext Paris, the IFF Shares will remain listed on the New York Stock Exchange (the “NYSE”), IFF’s primary listing exchange.
A voluntary sales facility procedure on the NYSE will be implemented by IFF for the benefit of its shareholders holding their IFF Shares through Euroclear France (the “Euronext Shareholders”), in accordance with Euronext rules (the “Sales Facility”). Accordingly, the Euronext Shareholders will have the following options:
- decide not to participate in the voluntary sales facility and keep their IFF Shares, which they will be able to trade on Euronext Paris through and including the trading day prior to the delisting date, and thereafter, only on the NYSE; or
- participate in the voluntary sales facility described below and sell all or part of their IFF Shares on the NYSE.
Euronext Shareholders not participating
Euronext Shareholders who do not wish to sell their IFF Shares pursuant to the Sales Facility, or otherwise have taken no action to tender their IFF Shares in the Sales Facility may only trade their IFF Shares on the NYSE following the delisting date. Any such holding and/or trade will be subject to the terms applied by their financial intermediary who will take the necessary steps to move their IFF Shares from Euroclear France to the relevant alternative central system for depositary.
Participating Euronext Shareholders
Euronext Shareholders who wish to sell their IFF Shares on the NYSE pursuant to the Sales Facility must request their financial intermediaries to deliver their IFF Shares from 24th November, 2020 to 8th December, 2020 included, to BNP Paribas Securities Services, acting as centralizing agent, pursuant to the procedure described in the applicable Euronext notice expected to be published on 20th November, 2020.
The IFF Shares delivered to BNP Paribas Securities Services will be sold on the NYSE starting on Monday,14th December 2020, by a broker, at market prices prevailing at the time of the sale.
BNP Paribas Securities Services will calculate the average sale price of the IFF Shares and will be in charge of transferring the sale proceeds to the participating Euronext Shareholders, calculated on the basis of the average sale price of the IFF Shares and converted into euros.
IFF will pay the fees for the centralization and the brokerage fee related to the sale on the NYSE of the IFF Shares delivered to BNP Paribas Securities Services and sold pursuant to the Sales Facility.
Euronext Shareholders are reminded that they may tender their IFF Shares in the Sales Facility on a voluntary basis.
No assurance can be given by IFF or BNP Paribas Securities Services as to the price at which the IFF Shares will actually be sold on the NYSE, the actual average sale price or the applicable currency exchange rate. This process is being implemented solely as an option to Euronext Shareholders and participation is not mandatory. Individual investors may thus determine not to participate in this process or may decide not to take any action in which case no assurance may be given as to the terms that will be applied by their financial intermediary in connection with or after the delisting. Individual investors are invited to consult their own investment advisors before making a decision to participate or not in this process.
The timetable of the Sales Facility and the delisting described above may be summarized as follows (it being specified that IFF reserves the right to amend this timetable):
Sales Facility |
|
Beginning of the Sales Facility
|
Tuesday 24th November 2020 (Tender period of 10 trading days) |
End of the Sales Facility |
Tuesday 8th December 2020 |
End of the centralization by BNP Paribas Securities Services |
Friday 11th December 2020 |
Sales on the New York Stock Exchange of the IFF Shares tendered in the Sales Facility |
Starting on Monday 14th December 2020 |
Proceeds of sale in USD converted into Euros |
Upon receipt of the funds by the bank |
Proceeds of sale distributed to the beneficiaries (i.e. , holders of IFF Shares having participated in the Sales Facility) |
Upon receipt of the funds by the bank |
Delisting |
|
Last day of trading of IFF Shares on Euronext Paris |
Thursday 17th December 2020 |
Delisting of IFF Shares from Euronext Paris |
Friday 18th December 2020 |
Euronext Shareholders participating in the Sales Facility acknowledge and agree to assume the risks associated with changes in the market price of IFF Shares and currency exchange rates that may occur between the time IFF Shares are delivered to BNP Paribas Securities Services and the sale of such IFF Shares on the NYSE as well as the date of conversion of the price into euros. All tender instruction of IFF Shares under the Sales Facility are irrevocable.
IFF Shares will be delisted from Euronext Paris on 18th December, 2020. IFF Shares will continue to be listed on the NYSE under the symbol “IFF”.
Shareholders are invited to contact their financial intermediaries for any additional information.
Welcome to IFF
At IFF (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF), we’re using Uncommon Sense to create what the world needs. As a collective of unconventional thinkers and creators, we put science and artistry to work to create unique and unexpected scents, tastes, experiences and ingredients for the products our world craves. Learn more at iff.com , Twitter , Facebook , Instagram , and LinkedIn .
Important Information
This press release is for information purposes only and does not constitute or form part of any advertisement, offer, solicitation or an invitation to make offers, sell, exchange or transfer, or any solicitation of any offer to subscribe for or purchase, or advertisement of, any securities, nor shall it (or any part of it) form the basis of any investment decision, contract or commitment whatsoever, and is provided for information only. The distribution of this press release may be restricted by law in certain jurisdictions, and persons into whose possession this press release or other information referred to herein come should inform themselves about and observe any such restriction. Any failure to comply with these restrictions may constitute a violation of the laws of any such jurisdiction.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201119006199/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis Conference9.10.2026 19:15:00 CEST | Press release
- Data on ALYFTREK in children ages 2 to 5 years demonstrate recovery of pancreatic function in some children –- Additional abstracts on clinical and real-world evidence on CFTR modulators also presented - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced new interim data from the ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) 2 to 5 years old open-label extension study, highlighting recovery of exocrine pancreatic function in some children in that age group, allowing those children to discontinue pancreatic enzyme replacement therapy (PERT). Pancreatic exocrine insufficiency in children with cystic fibrosis (CF) was previously believed to be irreversible. These data were presented at the North American Cystic Fibrosis Conference (NACFC). “The data presented at NACFC underscore the safety and efficacy of our CF medicines in the real world and in clinical trials in younger age groups. The data from the Phase 3 open-label study in 2 to 5 year olds evaluating exocrine p
Andersen Consulting udvider med TalentSmartEQ for at fremme lederskab og virksomhedstransformation9.10.2026 18:48:00 CEST | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for humankapital gennem en samarbejdsaftale med TalentSmartEQ, en San Diego-baseret virksomhed, der har fokus på at skabe praktiske, engagerende og handlingsorienterede læringsoplevelser med udgangspunkt i emotionel intelligens (EQ) og lederudvikling. I mere end to årtier har TalentSmartEQ arbejdet sammen med organisationer verden over med henblik på at udvikle ledelseskompetencer ved hjælp af emotionel intelligens og dermed styrke medarbejderengagement, teamwork og de samlede resultater. Virksomheden kombinerer forskningsbaserede metoder med praktiske læringsforløb, vurderinger, coaching og skræddersyede programmer, der skal omsætte opbygningen af emotionel intelligens til vedvarende ændringer i adfærden på arbejdspladsen. Som førende aktør i branchen samarbejder TalentSmartEQ med organisationer lige fra Fortune 500-virksomheder til offentlige myndigheder og privatejede virksomheder. "Organisationer stiller stadig større krav til dere
Verdant Rock Receives A (low) Financial Strength Rating from Morningstar DBRS, Adding a Second International Investment-Grade Assessment9.10.2026 16:00:00 CEST | Press release
Verdant Rock now holds Financial Strength Ratings from both Fitch Ratings and Morningstar DBRS, providing counterparties with dual-agency confirmation and reinforcing the security architecture behind each financial guarantee Verdant Rock Limited, a Bermuda Monetary Authority-regulated Class 3B insurance company, has received an A (low) Financial Strength Rating from Morningstar DBRS. The rating reflects Verdant Rock’s financial strength and its capacity to meet policyholder obligations as an investment-grade financial guarantor for Emerging Markets credit. Morningstar DBRS is a global credit rating agency with coverage across North America, Europe, Asia, and Latin America. Its assessment of Verdant Rock reflects the company’s strong projected earnings ability, robust risk profile, sound liquidity, and good capitalization. Morningstar DBRS also assigned an A (low) Issuer Rating to Verdant Rock. The rating follows Verdant Rock’s BBB+ Long-Term Insurer Financial Strength Rating with a Sta
Tecnotree Named a Visionary in the Inaugural 2026 Gartner® Magic Quadrant™ for CSP AI-Enabled Marketing and Sales Solutions9.10.2026 15:17:00 CEST | Press release
We think Gartner recognizes Tecnotree's open, governed approach to agentic AI as operators make AI the engine of their revenue operations Tecnotree, a global digital platform and services leader for AI, 5G, and cloud-native technologies, today announced that Gartner has positioned it as a Visionary in the first-ever Magic Quadrant for AI-Enabled CSP Marketing and Sales Solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261009905430/en/ Tecnotree Named a Visionary in the Inaugural 2026 Gartner® Magic Quadrant™ for CSP AI-Enabled Marketing and Sales Solutions A new category for a new operating model. CSPs are fighting saturated markets, rising acquisition costs, and accelerating churn. They are responding with AI-driven automation across the full revenue cycle, from segmentation and campaigns to lead management, CPQ, and renewals, increasingly executed by autonomous agents. According to us, Gartner creation of this Magi
Positive New Data on Corcym’s Perceval Plus Sutureless Aortic Heart Valve Encompasses up to 7-Year Follow-up9.10.2026 15:15:00 CEST | Press release
Data Presented at Annual Meeting of European Association for Cardio-Thoracic Surgery (EACTS), Along with 6 Perceval Plus E-PostersEACTS Also Marks Commercial Launch of TriMemo and Memo 4D Curve, Innovative Repair Devices for Tricuspid and Mitral Valves Corcym, a global medical device company dedicated to cardiac surgery, today announced that positive mid-term data from a sub-analysis of its Perceval Plus sutureless aortic heart valve as part of its MANTRA clinical trial was featured in an oral presentation today at the annual meeting of the European Association for Cardio-Thoracic Surgery (EACTS). The study is the longest follow-up available for Perceval Plus and the FREE tissue treatment from an international multicenter study, and demonstrated excellent durability, safety and quality of life improvements. Perceval Plus is the only sutureless and collapsible aortic surgical heart valve. Its unique design performs in any surgical scenario and is optimal for endoscopy and robotics. The
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
